| Literature DB >> 26288116 |
Katia Borgia Barbosa Pagnano1, Israel Bendit2, Carla Boquimpani3, Carmino Antonio De Souza1, Eliana C M Miranda1, Ilana Zalcberg4, Irene Larripa5, Luciana Nardinelli2, Rosana Antunes Silveira1, Laura Fogliatto6, Nelson Spector7, Vaneuza Funke8, Ricardo Pasquini8, Vania Hungria9, Carlos Sérgio Chiattone9, Nelma Clementino10, Monika Conchon11, Elena Beatriz Moiraghi12, Jose Luis Lopez13, Carolina Pavlovsky14, Miguel A Pavlovsky14, Eduardo E Cervera15, Luis Antonio Meillon16, Belinda Simões17, Nelson Hamerschlak18, Alicia Helena Magarinos Bozzano19, Ernesto Mayta20, Jorge Cortes21, Raquel M Bengió5.
Abstract
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.Entities:
Keywords: BCR-ABL mutations; Chronic myeloid leukemia; Imatinib; Resistance; Tyrosine kinase inhibitors
Mesh：
Substances：
Year: 2015 PMID： 26288116 DOI： 10.3109/07357907.2015.1065499
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176